Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 17/20 | 0.47 |
| ▸ | MTOR | P42345 | 16/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 12/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4329444 | 0.90 | PIK3CA (0.47) | PIK3CAMTORPIK3CGCNR2 | |
| SCHEMBL1432572 | 0.86 | PIK3CA (0.48) | PIK3CAMTORPIK3CG | |
| SCHEMBL1429410 | 0.86 | PIK3CA (0.48) | PIK3CAMTORPIK3CG | |
| SCHEMBL4318555 | 0.85 | PIK3CA (0.54) | PIK3CAMTORPIK3CGCNR2 | |
| SCHEMBL4330181 | 0.84 | PIK3CA (0.53) | PIK3CAMTORPIK3CGCNR2 | |
| SCHEMBL4316104 | 0.84 | PIK3CA (0.49) | PIK3CAMTORPIK3CGCNR2 | |
| SCHEMBL4327240 | 0.79 | PIK3CA (0.48) | PIK3CAMTORPIK3CGCNR2 | |
| SCHEMBL4315772 | 0.77 | PIK3CA (0.58) | PIK3CAMTORPIK3CGCNR2 | |
| SCHEMBL1429656 | 0.76 | PIK3CA (0.47) | PIK3CAMTORPIK3CG | |
| SCHEMBL1429658 | 0.76 | PIK3CA (0.47) | PIK3CAMTORPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090311217-A1 | 3-SUBSTITUTED-1H-INDOLE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090311217-A1 | 3-SUBSTITUTED-1H-INDOLE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | MTOR, RICTOR, PDPK1 | PIK3CA 4/4885MTOR 1/4885PIK3CG 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.